Immune-mediated hemolytic anemia (IMHA) is a life-threatening condition where the immune system attacks red blood cells, requiring intensive treatment and causing significant suffering in affected dogs.
IMHA causes acute, severe suffering. Dogs experience extreme fatigue from oxygen deprivation, labored breathing as the body struggles to compensate, and weakness that may prevent normal movement. The acute phase of the disease, before treatment takes effect, involves profound physiological distress. Hospitalization for intensive care including IV medications and blood transfusions is stressful for many dogs. Immunosuppressive treatment causes its own welfare concerns including increased infection susceptibility, gastrointestinal side effects, and behavioral changes. The high mortality rate means many affected dogs face end-of-life decisions during an acute crisis. Survivors may relapse, creating chronic anxiety for owners and repeated welfare challenges for affected dogs.